An Alexion employee working in a lab

CONDITIONS WE TREAT

Understanding Rare Diseases, Every Day

We’re dedicated to delivering life-changing medicines for those with rare and devastating diseases. Our innovation begins when we understand the challenges that people living with these rare diseases and their families face every day.

Julia, diagnosed with aHUS at 15 years old, riding bikes with her sister

aHUS

Atypical Hemolytic Uremic Syndrome

aHUS is an ultra-rare genetic, chronic, potentially life-threatening disease that can progressively damage vital organs, such as the kidneys.1

LEARN MORE
Roberta, diagnosed with gMG at 16 years old

gMG

Generalized Myasthenia Gravis

gMG is a debilitating, chronic and progressive autoimmune neuromuscular disease that can occur at any age but most commonly begins for women before the age of 40 and men after the age of 60.2-5

LEARN MORE
Tanner, diagnosed with HPP at 4 days old, with a stuffed animal

HPP

Hypophosphatasia

HPP is a genetic, chronic, progressive, and life-threatening metabolic disease in which patients experience devastating effects on multiple systems of the body, leading to debilitating or life-threatening complications.6

 

LEARN MORE
Albie, diagnosed with LAL-D as an infant, holding a puppy

LAL-D

Lysosomal Acid Lipase Deficiency

LAL-D is a genetic, chronic and progressive ultra-rare metabolic disease in which uncontrolled accumulation of cholesteryl esters and triglycerides may lead to multi-organ damage in infant, pediatric, and adult patients and premature death in infants.7

LEARN MORE

NF1 PN

Neurofibromatosis Type 1 Plexiform Neurofibromas

NF1 is a rare, progressive, genetic condition impacting multiple body systems characterized by benign tumors called plexiform neurofibromas (PN) that develop along nerve sheaths throughout the body.8-11 Depending on their size and location, PN can cause a range of clinical issues.12,13

LEARN MORE
KIM

NMOSD

Neuromyelitis Optica Spectrum Disorder

NMOSD is a rare and devastating complement-mediated disorder of the central nervous system (CNS) characterized by relapses where each individual attack results in cumulative disability.14-18

LEARN MORE
Joe, diagnosed with PNH at 24 years old, training for mixed martial arts

PNH

Paroxysmal Nocturnal Hemoglobinuria

PNH is a chronic, progressive, debilitating, and potentially life-threatening ultra-rare blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells).13,14

LEARN MORE
Related Topics

See how we’re serving people living with rare diseases

MEDICINES

Discover how we’re pushing the boundaries of rare disease research every day

PIPELINE

References:

  1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676-1687.
  2. Huda R, Tüzün E, Christadoss P. Targeting complement system to treat myasthenia gravis. Rev Neurosci. 2014;25(4):575-583.
  3. Howard JF, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized Myasthenia Gravis. Muscle Nerve. 2013;48(1):76-84.
  4. National Institute of Neurological Disorders and Stroke. Myasthenia Gravis Fact Sheet. http://www.ninds.nih.gov/disorders/myasthenia_gravis/detail_myasthenia_gravis.htm. Accessed October 22, 2019.
  5. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475-490.
  6. Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013;10(suppl 2):380-388.
  7. Kanuma® [package insert]. New Haven, CT: Alexion Pharmaceuticals, Inc; 2015.
  8. Tonsgard JH. Clinical manifestations and management of neurofibromatosis type 1. Semin Pediatr Neurol. 2006;13(1):2-7.
  9. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: A multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834-843.
  10. Blakeley JO, Plotkin SR. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol. 2016;18(5):624-638.
  11. Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology. 2013;81(21 Suppl 1):S33-S40.
  12. Korf BR, Rubenstein AE. Neurofibromatosis: A Handbook for Patients, Families, and Health Care Professionals. New York, NY: Thieme Medical Publishers; 2005.
  13. Hersh JH. Health supervision for children with neurofibromatosis. Pediatrics. 2008;121(3):633-642.
  14. Wingerchuk DM. Neuromyelitis optica spectrum disorders: critical role of complement-dependent cytotoxicity. Neurology Reviews. 2017;(suppl):S1-S4.
  15. Mealy MA, Boscoe A, Caro J, Levy M. Assessment of patients with neuromyelitis optica spectrum disorder using the EQ-5D. Int J MS Care. 2019;21(3):129-134.
  16. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.
  17. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135(pt 6):1834-1849.
  18. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013;81(14):1197-1204.
  19. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253-1258.
  20. Kelly R, Richards S, Hillmen P, Hill A. The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Ther Clin Risk Manag. 2009;5:911-921.

US/ALL-A/0042

The Trendys, diagnosed at 17, 14, 11, and 9 with LAL-D
Now we knew what we were up against, we knew we could fight.”
REBECCA, MOM OF THE TRENDY BROTHERS LIVING WITH LAL-D

HEAR THEIR STORY
You are now leaving www.alexion.com, a website provided by Alexion Pharmaceuticals, Inc. This link will take you to a different site to which this Privacy Policy does not apply.
CONFIRM
You are now leaving the alexion.com UK webpage for the global alexion.com website. The content on the global site is intended for a U.S. audience only
CONFIRM